Asklepios Group Reports Solid Third Quarter and Secures New Financing

The Asklepios Group has announced a strong third quarter for 2025, marked by increased patient numbers and successful financial maneuvers. From January to September, patient numbers rose 6.3% to 2.9 million, driven mainly by outpatient growth.

During this period, the group's consolidated revenue increased by 9.6% to EUR 4,770.1 million, with net income after tax reaching EUR 114.5 million. Total investments during this timeframe amounted to EUR 302.8 million.

A notable achievement was the successful placement of a EUR 600.0 million Social Schuldschein loan. This financing, under the Social Finance Framework, was implemented to refinance maturities from 2025 to 2027, attracting interest from both existing and international investors.

CFO Hafid Rifi expressed optimism, citing strong international investor interest as evidence of trust in Asklepios's sustainable strategy.